Results 31 to 40 of about 10,401 (200)

Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma : results from two phase 3, randomised, double-blind, placebo-controlled trials [PDF]

, 2020
BACKGROUND: Reslizumab 3 mg/kg administered intravenously is approved for the treatment of severe eosinophilic asthma. We assessed the safety and efficacy of subcutaneous reslizumab 110 mg in two trials in patients with uncontrolled severe asthma and ...
Adir, Yochai, Bernstein, Jonathan A, Brusselle, Guy, Castro, Mario, Garin, Margaret, Hickey, Lisa, Humbert, Marc, Jacobs, Joshua, Marsteller, Douglas A, Maspero, Jorge Fernando, McElhattan, Jennifer, Murphy, Kevin, Vanlandingham, Rebecca, Virchow, J Christian   +13 more
core   +1 more source

We Have to Learn to Do Without Knowing Enough: Anti-Eosinophilic Treatments for Severe Asthma [PDF]

, 2018
Interleukin.5 (IL.5) is the main eosinophilic cytokine that promotes the differentiation, survival, and activation of eosinophils, which are the key inflammatory cells in severe eosinophilic asthma .Thus, it is no surprise that ...
4,, BEGHE', Bianca, Fabbri, Lm3, Papi, A1   +3 more
core   +1 more source

Mepolizumab.

Australian prescriber
  +14 more sources

Asthma referrals : a key component of asthma management that needs to be addressed [PDF]

, 2017
Peer reviewedPublisher ...
Bergen, David A, Bjermer, Leif, Martinez, Rafael, Price, David   +3 more
core   +1 more source

Elevated mepolizumab levels in patients with severe asthma responsive to 1 year’s mepolizumab treatment

Journal of Allergy and Clinical Immunology: Global
Background: Asthma involves variable airflow limitation and persistent airway inflammation. Eosinophilic asthma, characterized by cytokine-mediated type 2 inflammation, is generally treated with inhaled corticosteroids.
Takayasu Nishimaki, MD, Hitoshi Sasano, MD, PhD, Sonoko Harada, PhD, Tomohito Takeshige, MD, PhD, Yuuki Sandhu, MD, PhD, Yuki Tanabe, MD, Kei Matsuno, MD, PhD, Tetsutaro Nagaoka, MD, PhD, Jun Ito, MD, PhD, Ryo Atsuta, MD, PhD, Mayu Ohuchi, PhD, Shigehiro Yagishita, MD, PhD, Akinobu Hamada, PhD, Kazuhisa Takahashi, MD, PhD, Norihiro Harada, MD, PhD   +14 more
doaj   +1 more source

Successful and safe treatment of severe steroid depended eosinophilic asthma with mepolizumab in a woman during pregnancy

Respiratory Medicine Case Reports, 2023
A 26-year-old female with steroid dependent eosinophilic asthma and nasal polyps who had successfully been treated with mepolizumab for 17 consecutive months with complete steroid withdrawal and symptoms control, stopped biologic treatment due to ...
Stylianos K. Vittorakis, Georgia Giannakopoulou, Konstantinos Samitas, Eleftherios Zervas   +3 more
doaj   +1 more source

Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population [PDF]

, 2017
Acknowledgments The authors thank Derek Skinner (Cambridge Research Support Ltd, Oakington, Cambridge, UK) for assistance with data extraction.Peer reviewedPublisher ...
Gibson, Danny, Golam, Sarowar, Hillyer, Elizabeth V, Kerkhof, Marjan, Price, David B, Soriano, Joan B, Tran, Trung N   +6 more
core   +1 more source

Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial

Allergy, Asthma & Clinical Immunology, 2019
Limited information is available on the clinical course of patients with severe asthma following discontinuation of biologic treatment. Therefore, a post hoc analysis was conducted in patients with severe eosinophilic asthma who participated in the ...
Hector Ortega, Catherine Lemiere, Jean-Pierre Llanos, Mark Forshag, Robert Price, Frank Albers, Steven Yancey, Mario Castro   +7 more
doaj   +1 more source

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database

Frontiers in Pharmacology, 2023
Mepolizumab is primarily used in the treatment of asthma, eosinophilic granulomatosis with polyangiitis, eosinophilia syndrome, and chronic rhinitis with nasal polyps.
Fan Zou, Chengyu Zhu, Siyu Lou, Zhiwei Cui, Dan Wang, Yingyong Ou, Li Wang, Junyou Chen, Yuanbo Lan   +8 more
doaj   +1 more source

Eosinophil Apoptosis and Clearance in Asthma [PDF]

, 2013
Peer reviewedPublisher ...
Bickham U.R., Duval E., Fadok V.A., Fadok V.A., Gaipl U.S., Hart S.P., Luttmann W., Meagher L.C., Schwartz B.R., Walsh G.M.   +9 more
core   +3 more sources